Live
ePaper
Search
Live ePaper

Copyright 2025 - All Right Reserved.
ITV Network Ltd 2025

Home > India > GSK-MO-REZ ACHIEVES 62% CONFIRMED OBJECTIVE RESPONSE RATE & 12.2-MONTH MEDIAN DURATION OF RESPONSE IN PLATINUM-RESISTANT OVARIAN CANCER PHASE IB TRIAL

GSK-MO-REZ ACHIEVES 62% CONFIRMED OBJECTIVE RESPONSE RATE & 12.2-MONTH MEDIAN DURATION OF RESPONSE IN PLATINUM-RESISTANT OVARIAN CANCER PHASE IB TRIAL

Written By:
Last Updated: October 24, 2026 03:41:35 IST

Follow us on
Google News

Share

GSK-MO-REZ ACHIEVES 62% CONFIRMED OBJECTIVE RESPONSE RATE & 12.2-MONTH MEDIAN DURATION OF RESPONSE IN PLATINUM-RESISTANT OVARIAN CANCER PHASE IB TRIAL

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

MORE NEWS

UK government sets out $800 million of AI security funding
AI-discovered bugs may soon trigger fresh disruptions, cyber experts say
Browns carry momentum from comeback win into Titans clash
Picklum and Colapinto harness Portuguese Pipeline for WSL surf wins
Fever GM Amber Cox follows team president out of Indy
JetBlue creditors working with restructuring adviser PJT Partners, WSJ reports
SoftBank-backed OPay eyes up to $4.4 billion US IPO valuation
NBA Results
JetBlue creditors working with restructuring adviser PJT Partners, WSJ reports
Picklum and Colapinto harness waves for WSL surf wins in Portugal

Follow Us

Facebook Twitter Youtube Instagram

India News : Find Latest India News and Breaking News from India on Politics, Business, Entertainment, Technology, Sports, Lifestyle and more.

मुख्य श्रेणियाँ

Follow Us

Facebook Twitter Youtube Instagram

India News : Find Latest India News and Breaking News from India on Politics, Business, Entertainment, Technology, Sports, Lifestyle and more.

मुख्य श्रेणियाँ

Group Websites

QUICK LINKS

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?